Research Peptide Overview
CJC-1295 no DAC is a growth hormone releasing hormone analogue peptide derived from GHRH(1-29) with strategic amino acid modifications at positions 2, 8, 15, and 27. Researchers at Stroid UK Shop investigate this synthetic peptide for its interaction with GHRH receptors and subsequent modulation of growth hormone secretion pathways in experimental models. The “no DAC” designation indicates this variant lacks the drug affinity complex found in longer-acting formulations, resulting in a shorter half-life profile.
Laboratory Applications
This 29-amino acid sequence demonstrates selective binding affinity for GHRH receptors in preclinical research protocols. Scientists examine CJC-1295 no DAC for its role in pulsatile growth hormone release mechanisms without the extended duration characteristics of DAC-conjugated variants. Research applications focus on circadian hormone rhythm studies, pituitary axis function evaluation, and growth factor pathway analysis. The peptides category encompasses numerous compounds for endocrine research, while investigators may compare findings with SARMs research examining alternative anabolic pathways. Researchers studying CJC-1295 peptide variants analyse differences between DAC and non-DAC formulations for temporal release patterns.
Technical Specifications
| Molecular Weight | 3367.97 g/mol |
|---|---|
| CAS Number | 863288-34-0 |
| Purity | Verify with supplier |
| Form | Lyophilised powder |
| Storage | -20°C protected from light |
| Manufacturer | Ultima Peptides |
| Quantity | 2mg per vial |
Research Compliance
This product is strictly intended for in-vitro research purposes only and is not approved for human consumption, veterinary use, or clinical application. Researchers must handle according to laboratory safety protocols and maintain appropriate storage conditions to preserve peptide integrity. Purchase requires institutional research credentials and adherence to applicable research regulations.
